BETA CELL METABOLISM

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 Newgard实验室采用跨学科方法研究葡萄糖刺激胰岛素分泌的生化和分子机制，包括开发新的细胞模型，基因发现和基因工程。 该计划项目资助（PPG）的总体目标仍然是开发2型糖尿病的新疗法。该计划已经从1999年的起源演变为达拉斯德克萨斯大学西南医学中心（UTSWMC）内的三个研究中心之间的合作，到目前的形式，涉及位于UTSWMC和杜克大学医学中心的四个中心的合作。该计划将继续以其独特的形式将糖尿病机制项目与专注于研究和治疗疾病的新技术开发的项目融合在一起。在过去的资助周期中，最引人注目的进展发生在胰岛生物学和相关技术领域。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Newgard laboratory uses interdisciplinary approaches for the study of the biochemical and molecular mechanisms involved in glucose-stimulated insulin secretion, including development of novel cellular models, gene discovery and genetic engineering. The overarching goal of this program project grant (PPG) continues to be the development of novel therapies for type 2 diabetes. The program has evolved from its genesis in 1999 as a collaboration between three research Centers within the University of Texas Southwestern Medical Center in Dallas (UTSWMC) to its current format, involving collaboration of four Centers located at UTSWMC and Duke University Medical Center. The program will continue with its unique format of melding projects on diabetes mechanisms with projects focused on development of new technologies for studying and treating the disease. In the past funding cycle, the most compelling advances have occurred in the area of pancreatic islet biology and related technologies.